Abstract
Purpose
This study evaluated the benefits of and possible contraindications to warfarin treatment in patients with atrial fibrillation (AF) prior to the introduction of new oral anticoagulants using health registry data from inpatient care, specialist ambulatory care, and primary care.
Methods
This is a cohort study including all patients in the region of Stockholm, Sweden (2.1 million inhabitants) with a diagnosis of non-valvular AF (n = 41 810) recorded during 2005–2009. The risks of suffering ischemic stroke, bleeding, or death with warfarin, aspirin, or no antithrombotic treatment during 2010 were related to CHA2DS2VASc scores, age, and complicating co-morbidities.
Results
One-year risks for ischemic stroke were 1.0–1.2 % with aspirin, 0–0.3 % with warfarin, and 0.1–0.2 % without treatment at CHA2DS2VASc scores 0–1. Among the aspirin-treated patients with CHA2DS2VASc scores ≥2, half had possible contraindications and high risks for ischemic stroke (5.2 %), bleeding (5.0 %), and death (19.3 %). The other half of the patients with no identified contraindications had a high risk for ischemic stroke (4.0 %) but a low bleeding risk (1.8 %) and a moderate mortality rate (8.4 %).
Conclusions
The present observations confirm earlier findings of undertreatment with warfarin and half of the high-risk patients treated with aspirin were obvious candidates for anticoagulant treatment. However, the other half of the patients had complicating co-morbidities, high bleeding risk, and poor prognosis. This and possible overtreatment of low-risk patients should be taken into account when considering more aggressive use of anticoagulant treatment.
Similar content being viewed by others
References
Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P (2012) ESC Committee for Practice Guidelines (CPG); 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33:2719–47
Forslund T, Wettermark B, Wandell P, von Euler M, Hasselstrom J, Hjemdahl P (2013) Risk scoring and thromboprophylactic treatment of patients with atrial fibrillation with and without access to primary healthcare data: experience from the Stockholm health care system. lnt J Cardiol 170:208–14
Friberg L, Rosenqvist M, Lip GY (2012) Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation 125:2298–307
Friberg L, Hammar N, Ring M, Pettersson H, Rosenqvist M (2006) Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Eur Heart J 27:1954–64
Hart RG, Pearce LA, Aguilar MI (2007) Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146:857–867
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL; American College of Cardiology; American Heart Association Task Force; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. Europace. 2006;8:651-745.
Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, Murray E (2007) BAFTA investigators; Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 370:493–503
Friberg L, Rosenqvist M, Lip GY (2012) Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182,678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 33:1500–10
Larsen TB, Lip GY, Skjøth F, Due KM, Overvad K, Hvilsted RL (2012) Added predictive ability of the CHA2DS2VASc risk score for stroke and death in patients with atrial fibrillation: the prospective Danish Diet, Cancer, And Health Cohort Study. Circ Cardiovasc Qual Outcomes 5:335–42
Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, Selmer C, Ahlehoff O, Olsen AM, Gislason GH, Torp-Pedersen C (2011) Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 342:d124
January CT, Wann LS, Alpert JS, Calkins H, Cleveland JC Jr, Cigarroa JE, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014 Apr 10. [Epub ahead of print]
Olesen JB, Lip GY, Lindhardsen J, Lane DA, Ahlehoff O, Hansen ML, Raunsø J, Tolstrup JS, Hansen PR, Gislason GH, Torp-Pedersen C (2011) Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a ‘real world’ nationwide cohort study. Thromb Haemost 106:739–749
Coppens M, Eikelboom JW, Hart RG, Yusuf S, Lip GY, Dorian P, Shestakovska O, Connolly SJ (2013) The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. Eur Heart J 34:170–6
Ludvigsson J, Otterblad-Olausson P, Pettersson BU, Ekbom A (2009) The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol 24:659–667
Wändell P, Carlsson AC, Wettermark B, Lord G, Cars T, Ljunggren G (2013) Most common diseases diagnosed in primary care in Stockholm, Sweden 2011. Fam Pract 30:506–513
Zarrinkoub R, Wettermark B, Wändell P, Mejhert M, Ljunggren G, Kahan T (2013) The epidemiology of heart failure, based on data for 2.1 million inhabitants in Sweden. Eur J Heart Fail 15:995–1002
Carlsson AC, Wändell P, Ösby U, Zarrinkoub R, Wettermark B, Ljunggren G (2013) High prevalence of diabetes, depression, anxiety, hypertension, asthma and COPD in the total population of Stockholm, Sweden—a challenge for public health. BMC Public Health 13:670
Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, Heurgren M, Olausson PO (2011) External review and validation of the Swedish national inpatient register. BMC Public Health 11:450
Smith JG, Platonov PG, Hedblad B, Engstrom G, Melander O (2010) Atrial fibrillation in the Malmo Diet and Cancer study: a study of occurrence, risk factors and diagnostic validity. Eur J Epidemiol 25:95–102
Nilsson AC, Spetz CL, Carsjo K, Nightingale R, Smedby B (1994) [Reliability of the hospital registry. The diagnostic data are better than their reputation; in Swedish]. Lakartidningen 91:598–605
Ingelsson E, Arnlov J, Sundstrom J, Lind L (2005) The validity of a diagnosis of heart failure in a hospital discharge register. Eur J Heart Fail 7:787–791
Ragnarson Tennvall G, Apelqvist J, Eneroth M (2000) The inpatient care of patients with diabetes mellitus and foot ulcers. A validation study of the correspondence between medical records and the Swedish Inpatient Registry with the consequences for cost estimations. J Intern Med 248:397–405
Linnersjo A, Hammar N, Gustavsson A, Reuterwall C (2000) Recent time trends in acute myocardial infarction in Stockholm, Sweden. Int J Cardiol 76:17–21
Johansson LA, Westerling R (2000) Comparing Swedish hospital discharge records with death certificates: implications for mortality statistics. Int J Epidemiol 29:495–502
Rosén M (2002) National Health Data Registers: a Nordic heritage to public health. Scand J Public Health 30:81–85
Wettermark B, Hammar N, Fored M, Leimanis A, Otterblad Olausson P, Bergman U, Persson I, Sundström A, Westerholm B, Rosén M (2007) The new Swedish Prescribed Drug Register—opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 16:726–35
Sjalander S, Sjalander A, Svensson PJ, Friberg L (2014) Atrial fibrillation patients do not benefit from acetylsalicylic acid. Europace 16:631–8
Björck S, Palaszewski B, Friberg L, Bergfeldt L (2013) Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study. Stroke 44:3103–8
Acknowledgments
We are very grateful for help with the management and analysis of the databases received from Jamilette Miranda, Thomas Cars, and Gunnar Ljunggren at the Stockholm County Council.
Funding was from the Stockholm County Council. TF has also received grants from “Anna Wedholms stiftelse.” The funding source had no role in the design, analysis, or interpretation of the results, and thus, the authors were independent from the funding source.
STROBE statement
The study was conducted and reported in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) recommendations.
Conflict of Interest
All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare all authors had support from the Stockholm County Council. TF has also received grants from “Anna Wedholms stiftelse”; no financial relationships with any organisations that might have an interest in the submitted work in the previous 3 years; and no other relationships or activities that could appear to have influenced the submitted work.
Author information
Authors and Affiliations
Corresponding author
Additional information
All authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.
Electronic supplementary material
Below is the link to the electronic supplementary material.
ESM 1
(DOC 118 kb)
Rights and permissions
About this article
Cite this article
Forslund, T., Wettermark, B., Wändell, P. et al. Risks for stroke and bleeding with warfarin or aspirin treatment in patients with atrial fibrillation at different CHA2DS2VASc scores: experience from the Stockholm region. Eur J Clin Pharmacol 70, 1477–1485 (2014). https://doi.org/10.1007/s00228-014-1739-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-014-1739-1